🚀 Sign up Free for Public Company Valuation & Insights!
Sign up for free to get access to the best public company valuation and insights. Get started today and unlock the potential of your investments!
Sign up free Video Highlights
UCB 
Pharma / Pharmaceuticals and biotechnology
At a Glance | Core Facts | Company Due Diligence: | Industry Due Diligence: | Competitors | Stock Swings | News | Income | Balance | Cash Flow | Growth | Enterprise | Ratios | Metrics | Dividends | Risks | SWOT | Porter's Five Forces | PEST | Score Positive | Clusters | Reports | Web1. Credit Risk: UCB SA has significant exposure to credit risk, as its primary source of income is from lending activities. As such, any downturn in the economy that affects the customers' ability to repay their debts could have an impact on the company’s financial performance.
2. Interest Rate Risk: UCB SA is exposed to fluctuations in interest rates, which can affect the value of its loan portfolios and securities.
3. Operational Risk: As a financial institution, UCB SA is at risk from operational risks, such as equipment failure, data security breaches, and costly regulatory or legal issues.
4. Liquidity Risk: As much of its assets are loans, UCB SA is exposed to liquidity risk, which arises when liquidity dries up and the company is unable to meet its short-term obligations.
5. Market Risk: UCB SA is exposed to market risk from various sources, such as foreign currency, commodities, and equities markets. Changes in these markets can affect UCB SA’s profitability.
Wait! There's more — sign up for free or log in